For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
What Trump’s vaccine executive order actually does
Yesterday, President Trump signed an executive order directing federal health agencies to revise childhood vaccine recommendations, reducing the number of vaccines recommended for…
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Search Posts
Blog
This week in ridiculous regulations: Taconite and lab fees
President Biden delivered his State of the Union address. Super Tuesday primaries all but settled this year’s presidential combatants. The FTC has a full…
National Review
Covid Vaccines: An Update on Balancing Risks and Benefits
A new large, multi-country study has confirmed what previous smaller studies found: Covid-19 vaccines have risks. In particular, the messenger RNA (mRNA) vaccines from Pfizer…
City Journal
Ignoring the Science
A new CDC study reports that the first updated Covid-19 vaccine—the bivalent vaccine approved in fall 2022—was about 50 percent effective in blocking infection over a…
The Federalist Society
Explainer 62 – FDA’s Regulation of Laboratory Developed Tests
CEI’s Joel Zinberg joined a podcast hosted by The Federalist Society for the Regulatory Transparency Project on the FDA’s regulation of laboratory developed tests:…
National Review
When Science Is Not Science
Just 22 percent of all adults and 41 percent of those 65 and older — the most vulnerable group — have received the updated 2023–24 Covid-19…
Blog
When the FTC’s anti-merger goals overshadow the prospect of saving lives
The Fifth Circuit Court of Appeals recently issued a ruling on the important case of Illumina-Grail v. Federal Trade Commission. A unanimous…